Measles: The Sequel

No Comments

The unfortunately necessary recap of a previously eliminated disease.

Background: In 2000, the US achieved the elimination of measles, defined as the absence of sustained transmission of the virus for more than 12 months [3,7]. Unfortunately, this success was short-lived.  According to the CDC, more than 800 cases of measles in 23 states have already been confirmed from Jan. 1 through May 10, 2019 [3]. This resurgence in measles is frustrating as it has a safe and highly effective vaccine, and it has no animal reservoir to maintain circulation.  Failure to get vaccinated unfortunately stems from misconceptions about vaccine safety (i.e. now-debunked claim connecting vaccination and autism [4,5]), poor health education, lack of access to health care and complacency. Measles has persisted in countries like Madagascar and the Philippines, and new outbreaks are underway in Israel, Japan, Brazil and Ukraine.

Measles - The Sequel.graph


  • Worldwide, measles is the most common vaccine-preventable cause of death among children [1,3]
  • Period of infectivity is from three days prior to the onset of the rash up to five days following its appearance
  • Before the availability of an effective vaccine in 1963, measles was a ubiquitous disease [7]
  • Generally, all susceptible people exposed to an active case will acquire infection (i.e. Non-immune people have up to a 90% chance of contracting the disease [3,7])
  • Each person with measles could potentially go on to infect 9 – 18 more that are non-immune [3]
  • Transmission: Respiratory Airborne
  • Reservoir: Humans are the only natural host


  • Single stranded RNA virus
  • 1 serotype
  • Genus Morbillivirus
  • Family Paramyxoviridae


  • Transmission of measles is primarily person-to-person via respiratory droplets that can be viable in the air for up to two hours
  • After multiplication in the respiratory mucosa, the virus spreads to regional lymphoid cells and then via the blood stream to leukocytes in the reticuloendothelial system
  • Erythematous maculopapular-to-confluent rash that first appears on the forehead and behind the ears and then spreads inferiorly to involve the face, trunk and extremities (including the palms and soles) reaching the feet by Day 3



Signs & Symptoms:
  • Incubation period of 10 – 14 days
  • Most people infected will recover uneventfully after:
    • Prodrome of gradually increasing fever and URI symptoms (“barking” cough, coryza, conjunctivitis – the 3 C’s) occur two to four days prior to the appearance of the rash
      • Sometimes immunocompromised patients do not develop the rash [7]
    • Koplik spots (white papules on an erythematous base) on the buccal mucosa are pathognomonic and precede the rash by 24 to 48 hours
  • However, measles can also lead to complications (greatest risk in immunosuppressed patients):
    • Otitis media
    • Diarrhea
    • Keratoconjunctivitis (Measles can exacerbate vitamin A deficiency and lead to blindness)
    • Pneumonia (the leading cause of measles-related deaths – 1 to 2/1,000) [3,7]
    • Acute Disseminated Encephalomyelitis (ADEM) and Measles Inclusion-Body Encephalitis (1 in 1, 000 cases [3,7]) and result in permanent brain damage
    • Subacute Sclerosing Panencephalitis (SSPE) is a degenerative disease of the brain caused by measles that can occur 7 to 10 years after measles virus infection. This occurs in 1 in 10,000 – 100,000 cases of measles [2,3]
  • People at high risk for Complications [7]:
    • Age <5 years
    • Adults aged >20 years
    • Pregnant women
    • Compromised immune systems (i.e. on chemotherapy, HIV infection, etc)
Acceptable Evidence of Immunity per the CDC [7]:
  • Written documentation of adequate vaccination:
    • One or more doses of measles-containing vaccine administered on or after the first birthday for preschool-age children and adults not at high risk
    • Two doses of measles-containing vaccine for school-age children and adults at high risk, including college students, healthcare personnel and international travelers
  • Laboratory evidence of immunity
  • Laboratory confirmation of measles
  • Birth before 1957
  • IgM antibody in serum and measles RNA by real-time polymerase chain reaction (RT-PCR) from a throat swab (or nasopharyngeal swab)
  • Urine samples may also contain virus and when feasible, collect both a respiratory and urine sample to increase the likelihood of detecting the virus


Immediate Management:
  • There is no specific antiviral therapy for measles
  • Treatment of the primary disease is supportive
  • Severe measles cases among children, such as those who are hospitalized should be treated with vitamin A and repeated again the next day:
    • 50,000IU for infants younger than 6mos of age
    • 100,000IU for infants 6 – 11 months of age
    • 200,000IU for children 12 months of age and older


  • Children: Primary prevention is via vaccination. All vaccines are highly effective (Up to 97% protection when given as 2 doses):
    • 1st MMR dose at 12- to 15-months of age
    • 2nd MMR dose at school entry (4 to 6 years of age) or at least 28 days following the first dose
  • Students at Post-High School Educational Institutions: Revaccination should occur in people entering educational institutions after high school or entering hospital service and have not had either a documented case of measles or the two-dose regimen
    • Students at post-high school educational institutions without evidence of measles immunity need two doses of MMR vaccine, with the second dose administered no earlier than 28 days after the first dose
  • Adults: People who are born during or after 1957 who do not have evidence of immunity against measles should get at least one dose of MMR vaccine
  • International Travelers: People 6 months of age or older who will be traveling internationally should be protected against measles before traveling internationally:
    • Infants 6 mos. through 11 months should receive one dose of MMR vaccine
    • Children 12 months of age or older should have documentation of two doses of MMR vaccine (the first does of MMR vaccine should be administered at age 12 months or older; the second dose no earlier than 28 days after the first dose)
    • Teenagers and adults born during or after 1957 without evidence of immunity against measles should have documentation of two doses of MMR vaccine, with the second dose administered no earlier than 28 days after the first dose
  • Post-exposure prophylaxis (PEP) provides permanent protection and may prevent disease if given within 72 hours of exposure
    • Except in health care settings, unvaccinated persons who receive their first dose of MMR vaccine within 72 hours post exposure may return to childcare, school, or work.
    • People with profound immunosuppression cannot be safely vaccinated with the live-attenuated vaccine and must rely on herd immunity to protect them from measles (Infants younger than 12 months of age, pregnant women without evidence of measles immunity, and people with severely compromised immune systems, should receive IG)
  • Immunoglobulin may prevent or modify disease if given within six days of exposure (Immunity provided by immunoglobulin is temporary)
    • Standard immunocompetent patient ≥12mos of age = Immunoglobulin 0.5mL/kg IM (up to 15mL)
    • Infants <12months of age = Immunoglobulin 0.5mL/kg IM (up to 15mL)
    • Pregnant women without evidence of immunity or severely immunocompromised patients = Immunoglobulin 400mg/kg IV
    • For infants aged 6 through 11 months MMR vaccine can be given in place of IG, if administered within 72 hours of exposure
    • Do not administer MMR vaccine and IG simultaneously, as this practice invalidates the vaccine
  • Severely immunocompromised patients include:
    • Bone marrow or stem cell transplant until at least 12 months after finishing all immunosuppressive treatment, or longer where the patient has developed graft versus host disease
    • Patients on treatment for all until at least six months after completion of immunosuppressive chemotherapy
    • Patients with a diagnosis of AIDS or HIV-infected persons with CD4  <200 lymphocytes/mm3 and those who have not received MMR vaccine since receiving effective anti-retroviral therapy
    • Some experts would include HIV infected persons who lack recent confirmation of immunologic status or measles immunity
Measles - The Sequel

Image Modified from [8]Measles - The Sequel.docx -

Image Created from Info on [7]


Take Home Points
  • There is a resurgence of measles worldwide
  • Incubation period is 10 to 14 days
  • Acute treatment is primarily supportive
  • Know the Post Exposure Prophylaxis (PEP) schedules and isolation times of various populations


  1. Tintinalli JE et al. Emergency Medicine: A Comprehensive Study Guide. McGraw-Hill 6th 2004.
  2. Marx JA et al. Rosen’s Emergency Medicine Concepts and Clinical Practice. Mosby Elsevier. 6th 2006.
  3. Paules CI et al. Measles in 2019 – Going Backward. NEJM 2019. PMID: 30995368
  4. Hviid A et al. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Ann Intern Med 2019. PMID: 30831578
  5. Taylor LE et al. Vaccines are Not Associated with Autism: An Evidence Based Meta-analysis of Case-Control and Cohort Studies. Vaccine 2014. PMID: 24814559
  6. Cousins S. Measles: A Global Resurgence. Lancet Infect Dis 2019. PMID: 31002077
  7. CDC: Measles (Rubeola) for Healthcare Professionals. [Link is HERE]
  8. Tunis MC et al. Updated NACI Recommendations for Measles Post-Exposure Prophylaxis. Can Commun Dis Rep 2018. PMID: 31015814


EDITOR-IN-CHIEF Dr. Rezaie is founder and editor of R.E.B.E.L EM.

Leave A Reply